Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Vor Biopharma Inc. (NYSE:VOR) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $6.0667.

A number of equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Vor Biopharma in a research note on Thursday, August 14th. Wedbush reissued an “outperform” rating on shares of Vor Biopharma in a research note on Thursday, June 26th.

Insider Activity

In other news, major shareholder Reprogrammed Interchange Llc sold 806,351 shares of the company’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $2.01, for a total value of $1,620,765.51. Following the completion of the sale, the insider directly owned 36,884,567 shares of the company’s stock, valued at $74,137,979.67. This represents a 2.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders sold 5,745,614 shares of company stock worth $11,195,853. 0.45% of the stock is currently owned by insiders.

Institutional Trading of Vor Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in Vor Biopharma in the first quarter valued at about $140,000. Two Sigma Investments LP grew its position in shares of Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after purchasing an additional 25,930 shares during the period. Northern Trust Corp increased its stake in Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after purchasing an additional 44,252 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Vor Biopharma during the 1st quarter worth approximately $100,000. Finally, Goldman Sachs Group Inc. lifted its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after buying an additional 58,247 shares in the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Trading Down 3.2%

Shares of NYSE:VOR opened at $1.52 on Thursday. The stock has a market capitalization of $192.56 million, a P/E ratio of -0.92 and a beta of 2.05. Vor Biopharma has a 1-year low of $0.13 and a 1-year high of $3.29. The business has a 50-day moving average price of $2.06 and a two-hundred day moving average price of $1.14.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.